-transparent.png){kind=logo}
Serum free thyroxine (FT4) levels were measured in patients with Hashimoto's thyroiditis and Graves' disease who were seropositive for thyroid hormone autoantibodies. The methods used were equilibrium dialysis/radioimmunoassay (FT4 by equilibrium dialysis, Nichols Institute) and FT4 analog radioimmunoassay (Amerlex MFT4) before and after treatment of sera with 12.5% polyethylene glycol (PEG). Furthermore, FT4 measurement in the PEG-treated sera was done using two other analog radioimmunoassays (DPC FT4 Kit and N-FT4 Corning). Serum thyrotropin (TSH) concentration before and after i.v. infusion of thyrotropin releasing hormone (TRH) was measured in five cases of Hashimoto's thyroiditis and four cases of Graves' disease with thyroid hormone autoantibodies. Although FT4 determination by analog tracer radioimmunoassays showed unusually high values for the hormone, results obtained by an equilibrium dialysis/radioimmunoassay method showed compatible values with basal TSH. Furthermore, FT4 concentrations measured with Amerlex MFT4 after treatment of sera with 12.5% PEG, correlated well with the values obtained by equilibrium dialysis/radioimmunoassay (r = 0.98, P < 0.001). Similar results were obtained with two other analog FT4 radioimmunoassays after treatment of sera with PEG. These results indicate that real FT4 values in patients with thyroid hormone autoantibodies are compatible with basal TSH concentrations. The presence of thyroid hormone autoantibodies per se does not affect the control mechanism of the hypothalamo-pituitary-thyroid axis. It was concluded that measurement of basal TSH as well as FT4 values by either equilibrium dialysis/radioimmunoassay or analog radioimmunoassays after PEG treatment provides clinicians with valid information for assessment of the precise status of thyroid function in patients with thyroid hormone autoantibodies.
S Sakata, and
T Komaki, and
T Ogawa, and
H Takuno, and
I Matsui, and
H Sarui, and
N Kojima, and
J Takamatsu, and
K Miura
January 1997,
Acta oncologica (Stockholm, Sweden),
S Sakata, and
T Komaki, and
T Ogawa, and
H Takuno, and
I Matsui, and
H Sarui, and
N Kojima, and
J Takamatsu, and
K Miura
January 1994,
Acta oncologica (Stockholm, Sweden),
S Sakata, and
T Komaki, and
T Ogawa, and
H Takuno, and
I Matsui, and
H Sarui, and
N Kojima, and
J Takamatsu, and
K Miura
January 2021,
Endokrynologia Polska,
S Sakata, and
T Komaki, and
T Ogawa, and
H Takuno, and
I Matsui, and
H Sarui, and
N Kojima, and
J Takamatsu, and
K Miura
December 2017,
Postepy dermatologii i alergologii,
S Sakata, and
T Komaki, and
T Ogawa, and
H Takuno, and
I Matsui, and
H Sarui, and
N Kojima, and
J Takamatsu, and
K Miura
January 2017,
AACE clinical case reports,
S Sakata, and
T Komaki, and
T Ogawa, and
H Takuno, and
I Matsui, and
H Sarui, and
N Kojima, and
J Takamatsu, and
K Miura
January 1992,
Acta dermato-venereologica,
S Sakata, and
T Komaki, and
T Ogawa, and
H Takuno, and
I Matsui, and
H Sarui, and
N Kojima, and
J Takamatsu, and
K Miura
August 1994,
Clinica chimica acta; international journal of clinical chemistry,
S Sakata, and
T Komaki, and
T Ogawa, and
H Takuno, and
I Matsui, and
H Sarui, and
N Kojima, and
J Takamatsu, and
K Miura
December 1987,
Journal of endocrinological investigation,
S Sakata, and
T Komaki, and
T Ogawa, and
H Takuno, and
I Matsui, and
H Sarui, and
N Kojima, and
J Takamatsu, and
K Miura
May 2006,
Nihon rinsho. Japanese journal of clinical medicine,
S Sakata, and
T Komaki, and
T Ogawa, and
H Takuno, and
I Matsui, and
H Sarui, and
N Kojima, and
J Takamatsu, and
K Miura
January 2003,
Journal of the Royal Society of Medicine,
